Sihuan Pharmaceutical Holdings Group Future Growth
Future criteria checks 5/6
Sihuan Pharmaceutical Holdings Group is forecast to grow earnings and revenue by 117.7% and 25.5% per annum respectively. EPS is expected to grow by 123% per annum. Return on equity is forecast to be 6.7% in 3 years.
Key information
117.7%
Earnings growth rate
123.0%
EPS growth rate
Pharmaceuticals earnings growth | 12.7% |
Revenue growth rate | 25.5% |
Future return on equity | 6.7% |
Analyst coverage | Low |
Last updated | 16 Nov 2023 |
Recent future growth updates
Recent updates
A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Dec 05Health Check: How Prudently Does Sihuan Pharmaceutical Holdings Group (HKG:460) Use Debt?
Oct 31Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Aug 19Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Apr 21Is Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Worth HK$0.8 Based On Its Intrinsic Value?
Nov 03Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?
Oct 11Is There An Opportunity With Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 34% Undervaluation?
Jun 21Estimating The Intrinsic Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Mar 09A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Nov 28Sihuan Pharmaceutical Holdings Group (HKG:460) Seems To Use Debt Rather Sparingly
Sep 26We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO For Now
Jun 22How Does Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Fare As A Dividend Stock?
May 11Sihuan Pharmaceutical Holdings Group's (HKG:460) Shareholders May Want To Dig Deeper Than Statutory Profit
Mar 30How Much Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Do Insiders Own?
Mar 07Should You Buy Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) For Its Dividend?
Feb 07Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Jan 11Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?
Dec 21Why Sihuan Pharmaceutical Holdings Group's (HKG:460) CEO Pay Matters
Dec 07Is Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) A Risky Dividend Stock?
Jul 22Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 3,186 | 337 | N/A | 698 | 1 |
12/31/2024 | 2,733 | 107 | N/A | 328 | 1 |
12/31/2023 | 1,861 | -54 | -96 | 199 | N/A |
6/30/2023 | 1,773 | -2,041 | -697 | -300 | N/A |
3/31/2023 | 1,977 | -1,996 | -620 | -127 | N/A |
12/31/2022 | 2,181 | -1,951 | -543 | 46 | N/A |
6/30/2022 | 2,595 | -144 | -306 | 425 | N/A |
3/31/2022 | 2,817 | 141 | -183 | 545 | N/A |
12/31/2021 | 3,038 | 427 | -60 | 665 | N/A |
9/30/2021 | 3,304 | 681 | 63 | 740 | N/A |
6/30/2021 | 3,317 | 945 | 187 | 815 | N/A |
3/31/2021 | 2,891 | 727 | -83 | 521 | N/A |
12/31/2020 | 2,464 | 508 | -353 | 227 | N/A |
9/30/2020 | 2,370 | -14 | -429 | 214 | N/A |
6/30/2020 | 2,275 | -537 | -504 | 200 | N/A |
3/31/2020 | 2,577 | -1,623 | 162 | 809 | N/A |
12/31/2019 | 2,878 | -2,709 | 828 | 1,418 | N/A |
9/30/2019 | 3,088 | -1,927 | 1,238 | 1,726 | N/A |
6/30/2019 | 3,297 | -1,144 | 1,647 | 2,033 | N/A |
3/31/2019 | 3,107 | 238 | 1,525 | 1,913 | N/A |
12/31/2018 | 2,917 | 1,620 | 1,403 | 1,793 | N/A |
9/30/2018 | 2,751 | 1,496 | 1,481 | 1,906 | N/A |
6/30/2018 | 2,584 | 1,372 | 1,559 | 2,019 | N/A |
3/31/2018 | 2,665 | 1,411 | 1,495 | 1,968 | N/A |
12/31/2017 | 2,746 | 1,449 | 1,431 | 1,918 | N/A |
9/30/2017 | 2,992 | 1,632 | N/A | 1,889 | N/A |
6/30/2017 | 3,238 | 1,815 | N/A | 1,860 | N/A |
3/31/2017 | 3,212 | 1,761 | N/A | 1,939 | N/A |
12/31/2016 | 3,186 | 1,708 | N/A | 2,018 | N/A |
9/30/2016 | 2,984 | 1,528 | N/A | 2,037 | N/A |
6/30/2016 | 2,781 | 1,347 | N/A | 2,056 | N/A |
3/31/2016 | 2,974 | 1,705 | N/A | 1,812 | N/A |
12/31/2015 | 3,167 | 2,062 | N/A | 1,569 | N/A |
9/30/2015 | 3,321 | 2,181 | N/A | 1,691 | N/A |
6/30/2015 | 3,474 | 2,299 | N/A | 1,813 | N/A |
3/31/2015 | 3,279 | 1,985 | N/A | 1,787 | N/A |
12/31/2014 | 3,084 | 1,671 | N/A | 1,761 | N/A |
9/30/2014 | 2,365 | 1,581 | N/A | 1,650 | N/A |
6/30/2014 | 1,645 | 1,491 | N/A | 1,538 | N/A |
3/31/2014 | 2,116 | 1,388 | N/A | 1,556 | N/A |
12/31/2013 | 2,586 | 1,285 | N/A | 1,574 | N/A |
9/30/2013 | 4,355 | 1,182 | N/A | 1,408 | N/A |
6/30/2013 | 3,978 | 1,060 | N/A | 1,306 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 460 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: 460 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 460 is expected to become profitable in the next 3 years.
Revenue vs Market: 460's revenue (25.5% per year) is forecast to grow faster than the Hong Kong market (8.2% per year).
High Growth Revenue: 460's revenue (25.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 460's Return on Equity is forecast to be low in 3 years time (6.7%).